Merck reports positive late-stage trial results for personalized mRNA melanoma vaccine

Merck & Co. announced that its personalized mRNA vaccine demonstrated efficacy in reducing melanoma recurrence in a late-stage clinical trial. The report follows Moderna's separate announcement regarding a $2 billion bond issuance intended to fund oncology research, signaling increased capital allocation toward mRNA cancer therapeutics.